KIT and gastrointestinal stromal tumor: Conversely, other diseases characterized by hyperactivity of tyrosine kinases, such as PDGFRα in gastrointestinal stromal tumor (GIST) and hypereosinophilic syndrome or c-Kit in systemic mastocytosis, can benefit from imatinib and other inhibitors with wide selectivity spectrum [65].